Bae v. Shalala

44 F.3d 489, 1995 WL 2537
CourtCourt of Appeals for the Seventh Circuit
DecidedJanuary 4, 1995
DocketNo. 94-1373
StatusPublished
Cited by40 cases

This text of 44 F.3d 489 (Bae v. Shalala) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bae v. Shalala, 44 F.3d 489, 1995 WL 2537 (7th Cir. 1995).

Opinion

COFFEY, Circuit Judge.

Petitioner Kun Chae Bae, the former president of a generic drag manufacturing company, appeals the final order of the Food and Drag Administration (“FDA”) under the Generic Drag Enforcement Act of 1992 (“GDEA”), 21 U.S.C. §§ 335a-335c, permanently debarring him from “providing services in any capacity to a person that has an approved or pending drag product application.” The GDEA mandates permanent debarment for any individual “convicted of a felony under [fjederal law for conduct ... relating to the development or approval, ... or ... [other] regulation of any drag prod[491]*491uct” under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301-895.1 The FDA debarred Bae because of his 1990 felony conviction for aiding and abetting interstate travel in aid of racketeering, which arose from allegations that, in 1987, Bae provided an FDA official with an “unlawful gratuity” in exchange for “official acts performed and to be performed” by the FDA official. This case presents the question of whether and under what circumstances a civil debarment penalty may constitute retroactive punishment prohibited by the Ex Post Facto Clause of the United States Constitution.2 We affirm.

I. BACKGROUND

From 1973 through 1988, Bae was the president of My-K Laboratories, Inc., a generic drug manufacturing company located in suburban Chicago, Illinois. My-K Laboratories, like other generic drug manufacturers, sought FDA approval to market generic copies of previously approved drugs through the submission of abbreviated new drug applications. The 1984 amendments to the Federal Food, Drug, and Cosmetic Act authorized generic drug manufacturers, through the submission of abbreviated new drug applications, to rely on the FDA’s prior determination of the safety and effectiveness of an innovator’s drug, provided that the manufacturer demonstrated that the generic copy was fundamentally identical or “bioequiva-lent” to the innovator’s pharmaceutical product. See 21 U.S.C. § 355(j).

While president of My-K Laboratories, ■ Bae submitted several abbreviated new drug applications to the FDA’s Division of Generic Drugs. This division was composed of four chemistry review branches responsible for determining whether the manufacturing procedures and analytical controls described in the abbreviated new drug applications were adequate to assure the identity, strength, quality and purity of the drug products. Charles Y. Chang, the Branch Chief of the FDA’s chemistry review branch in Maryland, was responsible for supervising the chemists who evaluated My-K Laboratories’ abbreviated new drug applications. Bae frequently consulted with Chang concerning the status of My-K Laboratories’ new drug applications and sought advice from Chang on how to resolve various problems as they arose.

On two occasions, once in the summer of 1986 and once in the summer of 1987, Bae invited Chang to visit Bae’s country home in Illinois. On each of these visits, Bae gave Chang $10,000 in United States currency.

After Bae sold his interest in My-K Laboratories in 1988, he became the subject of an investigation of irregularities concerning the FDA’s drug approval process. In 1990, Bae was charged with and pleaded guilty to one felony count of aiding and abetting interstate travel in aid of racketeering, in violation of 18 U.S.C. §§ 1952 and 2. The Information3 alleged that on or about August 21,1987, Bae caused FDA Branch Chief Charles Y. Chang to travel from Maryland to Illinois with the intent to provide Chang with an “unlawful gratuity.” The Information further alleged that during Chang’s visit to Illinois, Bae gave Chang $10,000 “for and because of official acts performed and to be performed” by Chang. The statement of facts accompanying the Information asserted that Chang provided Bae “with several formulations for generic drugs which Chang had gleaned from other companies’ [applications].”

By certified letter dated March 30, 1993, the FDA notified Bae that it proposed to debar him from participation in the generic drug industry pursuant to 21 U.S.C. § 335a(a)(2) based on his prior felony conviction for conduct relating to the development or approval of a generic drug product. The FDA notified Bae that he would have the opportunity for an evidentiary hearing, should he desire to contest his debarment, if [492]*492he presented specific facts, in writing, demonstrating a genuine and substantial issue of fact relevant to his debarment. Bae requested a hearing, but submitted no specific facts, and instead raised the argument that the GDEA’s debarment provision was punitive in nature, and that its retroactive application to him violated the constitutional prohibition against ex post facto laws. The FDA, after reviewing Bae’s request for a hearing, denied the request, finding that Bae had failed to raise any genuine or substantial issue of fact relevant to his debarment. On December 30, 1993, the FDA issued a final order permanently debarring Bae from providing services in any capacity to a person with a pending or approved drug product application. 58 Fed. Reg. 69,368 (Food & Drug Admin.1993).

II. DISCUSSION

The Administrative Procedure Act, 5 U.S.C. §§ 701-706, governs our review of an action taken by an administrative agency. Bae’s challenge to the FDA’s debarment order raises a pure question of law: whether the retroactive application of the debarment penalty of the GDEA violates the Constitution’s prohibition against ex post facto laws. Our review of this question is de novo. See 5 U.S.C. § 706; Director, Office of Workers’ Compensation Programs v. Ball, 826 F.2d 603, 604 (7th Cir.1987).

The Ex Post Facto Clause of the United States Constitution, Article I, § 9, clause 3, prohibits the enactment of any law “which imposes a punishment for an act which was not punishable at the time it was committed; or imposes additional punishment to that then prescribed.” Cummings v. Missouri, 71 U.S. (4 Wah.) 277, 325-26, 18 L.Ed. 356 (1867); Dehainaut v. Pena, 32 F.3d 1066, 1073 (7th Cir.1994) (quoting Inglese v. United States Parole Comm’n, 768 F.2d 932, 934 (7th Cir.1985)). “[F]or a criminal or penal law to be ex post facto ... it must be retrospective, that is, it must apply to events occurring before its enactment, and it must disadvantage the offender affected by it.” Weaver v. Graham, 450 U.S. 24, 28, 101 S.Ct.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Blackman Hinds v. Holder
790 F.3d 259 (First Circuit, 2015)
United States v. Leach
639 F.3d 769 (Seventh Circuit, 2011)
State v. Kirkbride
2008 MT 178 (Montana Supreme Court, 2008)
State v. Rickman
2008 MT 142 (Montana Supreme Court, 2008)
Garner v. U.S. Department of Labor
114 F. Supp. 2d 514 (S.D. Mississippi, 1999)
Slugocki v. US BY AND THROUGH DEPT. OF LABOR
988 F. Supp. 1443 (S.D. Florida, 1997)
In Re Game Farm License Number 319 of Brogan
942 P.2d 100 (Montana Supreme Court, 1997)
ALAN A. v. Verniero
970 F. Supp. 1153 (D. New Jersey, 1997)
Taylor v. State of RI
First Circuit, 1996
State v. Harlin
925 P.2d 1149 (Supreme Court of Kansas, 1996)
Doe v. Pataki
940 F. Supp. 603 (S.D. New York, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
44 F.3d 489, 1995 WL 2537, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bae-v-shalala-ca7-1995.